United States: FDA Establishes Electronic Privacy, Security, And Reliability Criteria For Clinical Trial Records

Last Updated: August 1 2017
Article by Maureen Bennett, Kimberly Lovett Rockwell, Michele R. Goodman and Ann T. Hollenbeck
Most Read Contributor in United States, September 2019

In Short

The Situation: Technological advances and the growing use of electronic records and tools potentially raise privacy and security concerns in connection with certain FDA-related activities.

The Action: FDA has released a draft guidance to ensure that entities regulated by the Agency follow certain procedures and processes that must be in place to safeguard the electronic records used in clinical research activities and electronic submissions.

Looking Ahead: Stakeholders have until August 21, 2017, to direct comments on the draft guidance to FDA.

In March 1997, the Food and Drug Administration ("FDA") published a final rule, codified in 21 CFR Part 11 ("Part 11"), establishing the privacy, security, and reliability criteria for electronic records and electronic signatures used for certain FDA-related activities. FDA subsequently issued several draft guidance documents and a policy statement to clarify Part 11 but withdrew these documents in early 2003 amid concerns that certain of FDA's broad interpretations of the 1997 final rule would lead to prohibitively high costs of compliance and unintended hindrance on technological innovations.

Subsequently, in August 2003, FDA further clarified that it was conducting a reexamination of Part 11 and would exercise enforcement discretion during the reexamination period with regard to Part 11 compliance. In June 2017—more than 13 years after FDA began its reexamination—FDA issued draft guidance on the application of Part 11 to electronic records and electronic signatures used by sponsors, investigators, and third parties when engaged in clinical research activities ("2017 Draft Guidance").

FDA explained the necessity of this 2017 Draft Guidance as stemming from advances in technology and the growing use of electronic records and tools such as audit trails, validation processes, and automated date-and-time stamps. The purpose of the guidance is to ensure that entities regulated by FDA understand that certain procedures and processes must be in place to safeguard the authenticity, integrity, and, when appropriate, the confidentiality of electronic records used in clinical research activities and electronic submissions.

One important area touched upon by the 2017 Draft Guidance is electronic records validation processes. FDA makes clear that regulated entities should have and document "risk-based" validation plans for electronic systems, which should include consideration of the purpose, intended use, nature, and significance of the electronic systems. Such validation could include: processes such as system testing to demonstrate correct installation and functioning; requiring vendor documentation of validation; or documenting and testing any changes to the electronic systems. The 2017 Draft Guidance states that during FDA inspection, FDA will focus on ensuring that any critical data (e.g., lab values, study endpoint data) are not altered in meaning or value when transferred to another system or data format.

Another area of focus in the 2017 Draft Guidance is the use of mobile technology during clinical investigations. FDA has indicated that while regulated entities may use mobile technology to capture, record, or transmit data directly from study participants, certain safeguards must be in place to ensure user identity authenticity, proper tracking of data to a specific participant, data security and confidentiality during storage and transfer, and proper training of study participants in use of the mobile technology.

Highlights of the other items addressed in the 2017 Draft Guidance include:

  • FDA permits interchangeable use of electronic records, durable storage devices, and paper records for archiving purposes, assuming certain controls are in place to ensure their authenticity.
  • If regulated entities outsource electronic services to third-party service providers, the regulated entity remains responsible for meeting the Part 11 electronic systems regulatory requirements. As such, regulated entities should ensure certain validation, data integrity, authenticity, and confidentiality safeguards are in place before contracting with the third-party provider.
  • Electronic health records used in the provision of clinical/medical care are not currently subject to Part 11 requirements.
  • The audio, video, or live-chat telecommunications systems used in the provision of telemedicine services are not subject to Part 11 regulations; however, any systems used to store or forward audio, visual, or chat data or transcripts are subject to the regulations.
  • Although electronic systems must track user identity, date and time of signature, and meaning attached to any electronic signature, FDA does not mandate any specific form of electronic signature. Instead, electronic signature methods should be implemented based upon ensuring a reasonable likelihood of preventing fraudulent use.
  • FDA does not certify individual electronic systems or electronic signature methods. Instead, each regulated entity is responsible for ensuring its own Part 11 compliance in the use of various electronic systems and signature methods.

Beginning May 5, 2018, sponsors and investigators will be required to submit electronically all new drug applications, abbreviated new drug applications, certain biologics license applications, and all investigational new drug applications through FDA's eCTD system. In guidance issued in April 2017 ("Providing Regulatory Submissions in Electronic Format—Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications"), FDA identified the technical specification documents that regulated entities should use to organize these submissions.

FDA is accepting comments on the 2017 Draft Guidance through August 21, 2017.

Three Key Takeaways

  1. FDA's previous attempts at establishing privacy, security, and reliability criteria for electronic records and electronic signatures used for certain activities potentially came with prohibitively high compliance costs and a risk of hindering technological innovations.
  2. FDA's new 2017 Draft Guidance helps ensure that regulated entities understand the particular procedures and processes that must be in place to safeguard the electronic records used in clinical research activities and electronic submissions.
  3. Electronic records validation processes and the use of mobile technology during clinical investigations are areas of particular focus in the 2017 Draft Guidance.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions